SCHEMBL24257531

SCHEMBL24257531

Cc1c(-c2cnn(-c3ccccn3)c2)cnc(C#N)c1Cl

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 6/20 0.52
GRM4 Q14833 5/20 0.48
EGLN1 Q9GZT9 2/20 0.39
ALKBH2 Q6NS38 1/20 0.39
ADORA2A P29274 1/20 0.34
ADORA2B P29275 1/20 0.34
ADORA1 P30542 1/20 0.34
SLC11A2 P49281 1/20 0.33
DRD2 P14416 1/20 0.33
DRD4 P21917 1/20 0.33
DRD3 P35462 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.32
HTR2B P41595 1/20 0.32
MTNR1A P48039 1/20 0.32
KCNH2 Q12809 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24257502 0.85 GRM4 (0.53) GRM5GRM4SMN1; SMN2KDM4EALDH1A1
SCHEMBL24257812 0.80 GRM5 (0.46) GRM5GRM4EGLN1ALKBH2ADORA2A
SCHEMBL24257535 0.78 GRM4 (0.45) GRM5GRM4KDM4EHTR2BMTNR1A
SCHEMBL30453060 0.76 KDM4E (0.41) GRM5SMN1; SMN2KDM4EALDH1A1POLB
SCHEMBL24257776 0.76 KDM4E (0.41) GRM5SMN1; SMN2KDM4EALDH1A1POLB
SCHEMBL30796163 0.75 GRM5 (0.61) GRM5GRM4EGLN1ALKBH2ADORA2A
SCHEMBL5219316 0.75 GRM5 (0.61) GRM5GRM4EGLN1ALKBH2ADORA2A
SCHEMBL5216821 0.73 GRM4 (0.60) GRM5GRM4EGLN1ALKBH2ADORA2A
SCHEMBL24257592 0.73 KDM5A (0.37)
SCHEMBL24257513 0.72 KDM4E (0.38) SMN1; SMN2KDM4EALDH1A1POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
EP-4196466-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE Akebia Therapeutics Inc. (US) 2023-06-21 EP disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 GRM5 1946/4885GRM4 3161/4885EGLN1 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.